Scarica l'app Stockscreener
25.03
0.60%
0.15
Dopo l'orario di chiusura:
25.06
0.03
+0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$24.88
Aprire:
$24.92
Volume 24 ore:
19.32M
Relative Volume:
0.29
Capitalizzazione di mercato:
$142.31B
Reddito:
$62.79B
Utile/perdita netta:
$9.84B
Rapporto P/E:
14.59
EPS:
1.7156
Flusso di cassa netto:
$10.38B
1 W Prestazione:
-0.04%
1M Prestazione:
-0.75%
6M Prestazione:
+2.96%
1 anno Prestazione:
-6.39%
Intervallo 1D:
$24.91
$25.14
Intervallo di 1 settimana:
$24.83
$25.52
Portata 52W:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.03 | 141.46B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,076.98 | 959.14B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.78 | 495.78B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.89 | 404.36B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
138.88 | 266.96B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
106.45 | 260.71B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Is Pfizer a Quiet Opportunity After a 41% Three Year Share Price Slide? - simplywall.st
Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom - FinancialContent
Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025 - ts2.tech
Swedbank AB Has $123.91 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Vontobel Holding Ltd. Buys 95,393 Shares of Pfizer Inc. $PFE - MarketBeat
BofA Trims Pfizer (PFE) PT as COVID-19 Sales Slide and Obesity Focus Shifts to Metsera - Finviz
Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever - The Motley Fool
Pfizer Stock (PFE) After Hours Today, Dec. 24, 2025: Why Shares Rose in the Christmas Eve Session and What to Watch Before the Next Market Open - ts2.tech
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025) - ts2.tech
Pfizer’s Protonix Pediatric Study Completion: What Investors Should Watch Next - TipRanks
Pfizer Inc (NYSE:PFE) Advances Biopharmaceutical Operations Globally - Kalkine Media
Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts - ts2.tech
164,000 Shares in Pfizer Inc. $PFE Acquired by Value Partners Investments Inc. - MarketBeat
Ocular Implant Market is Thriving Worldwide | Novartis AG, Pfizer Inc., Staar Surgical, Johnson & Johnson Services - openPR.com
Pfizer (NYSE:PFE) Shares Flat After Clinical Update Disclosure - Kalkine Media
BayBridge Capital Group LLC Decreases Position in Pfizer Inc. $PFE - MarketBeat
Buy Or Sell Pfizer Stock? - Forbes
Did a Hympavzi Trial Death and Tighter Guidance Just Reframe Pfizer's (PFE) Risk–Reward Story? - Yahoo Finance
Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open - ts2.tech
Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Pfizer (NYSE:PFE) Stock Price Down 1.3%What's Next? - MarketBeat
Pfizer says patient dies after receiving hemophilia drug in trial - Reuters
Patient dies after taking Pfizer drug for hemophilia - Українські Національні Новини
Pfizer Confirms Death Of Patient Enrolled In Hemophilia Drug Study - Stocktwits
Hemophilia trial death with Pfizer’s Hympavzi under scrutiny - BioWorld MedTech
Pfizer Reports Participant's Death in Hympavzi Extension Study in Hemophilia - marketscreener.com
Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching - ts2.tech
Participant death reported in Pfizer hemophilia trial, letter shows - marketscreener.com
Pfizer Stock Is Down -- Patient Death in Hemophilia Study Raises Safety Concerns - Yahoo Finance
Pfizer says does not anticipate any impact to safety for patients treated with approved marstacimab - marketscreener.com
Patient dies after receiving Pfizer’s hemophilia drug Hympavzi By Investing.com - Investing.com Nigeria
Pfizer reports patient death in hemophilia trial for Hympavzi - Seeking Alpha
Patient dies after receiving Pfizer’s hemophilia drug Hympavzi - Investing.com
Patient Dies After Taking Pfizer’s Drug for Blood Disorder - Bloomberg.com
Welch Group LLC Boosts Stake in Pfizer Inc. $PFE - MarketBeat
Flagship Pioneering announces TCR bispecific program with Pfizer - BioWorld MedTech
Macrolide Antibiotics Market Overall Study Report 2025-2032 | - openPR.com
Pfizer (PFE) Valuation Check as Padcev–Keytruda Success and Obesity Deals Recast Its Post‑COVID Growth Story - simplywall.st
Pfizer Inc. $PFE Shares Bought by Generali Investments CEE investicni spolecnost a.s. - MarketBeat
Pfizer Limited (PFIZER) Stock RalliesValue Traps to Avoid & The Future of Wealth Is Just a Click Away - Bollywood Helpline
Pfizer (PFE) Stocks: Oncology and Obesity Deals Drive Investor Optimism - parameter.io
Pfizer: Downgrade To 'Hold' On Lower 2026 Revenue Guidance And Potential Growth Tracks - Seeking Alpha
Jim Cramer on Pfizer: “I’m Going to Say Just Weak Hold” - Insider Monkey
Jim Cramer on Pfizer: "I'm Going to Say Just Weak Hold" - Finviz
Wedge Capital Management L L P NC Has $26.91 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025) - ts2.tech
First Bank & Trust Buys 80,401 Shares of Pfizer Inc. $PFE - MarketBeat
Foster Victor Wealth Advisors LLC Purchases 60,667 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching - ts2.tech
Why Pfizer Inc. (Common Stock) (PFEB) stock could rally stronglyJuly 2025 EndofMonth & Weekly Return Optimization Plans - ulpravda.ru
Voya Investment Management LLC Acquires 688,225 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):